title: Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer.
abstract: Targeting angiogenesis is proving to be a successful approach in the management of ovarian cancer. The vascular endothelial growth factor inhibitor, bevacizumab, is the first angiogenesis inhibitor to have shown a significant progression-free survival advantage in the Phase III setting. There is now evidence supporting the use of bevacizumab in combination with chemotherapy for first-line and relapsed (platinum-sensitive and resistant) ovarian cancer. In this review, we summarize the positive Phase III trial (OCEANS [Ovarian Cancer Study Comparing Efficacy and Safety of Chemotherapy and Anti-Angiogenic Therapy in Platinum-Sensitive Recurrent Disease]) that led to European Medicines Agency approval of bevacizumab in platinum-sensitive first relapse and discuss the best use of the drug in this disease.
authors: Gynecology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
authors: Chiara
authors: C
authors: Della Pepa
authors: Gynecology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
authors: Susana
authors: S
authors: Banerjee
keywords: antiangiogenic; ovarian; recurrent